Biotech Values

[rkrw]

It would be expensive to acquire. So they buy the whole company at some price, then they'd have to eat the expense of the trial, la jolla burning about $17M or so per quarter. I doubt m&a was ever considered. The way its structured Biomarin pays but its on la jolla's books, so its not a P&L hit for bmrn.

Hindsight will be 20-20 but there's no such thing as 50/50 with a lupus trial. Cellcept is a standard of care in lupus, published in the NEJM, even that failed.

<<Personally if lets say there is a 50/50 chance of success I would like BMRN to do 2-3 more of these deals and say we get one solid product out of it wouldn't be too bad in my book>>